Consistently, we have demonstrated the effect of osteolytic breast cancer bone metastases on muscle weakness and muscle fiber atrophy via bone-matrix–derived TGF-ß and activated p38/NF-κB signaling cascade [27••]. This evidence concerns the gene NFKB1 and breast cancer.